These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35682540)

  • 1. Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.
    Yagolovich AV; Artykov AA; Isakova AA; Vorontsova YV; Dolgikh DA; Kirpichnikov MP; Gasparian ME
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli.
    Isakova A; Artykov A; Vorontsova Y; Dolgikh D; Kirpichnikov M; Gasparian M; Yagolovich A
    Mol Biotechnol; 2023 Apr; 65(4):581-589. PubMed ID: 36094644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
    J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
    Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Efficient Method for Production of Recombinant Antitumor Cytokine TRAIL and Its Receptor-Selective Variant DR5-B.
    Yagolovich AV; Artykov AA; Dolgikh DA; Kirpichnikov MP; Gasparian ME
    Biochemistry (Mosc); 2019 Jun; 84(6):627-636. PubMed ID: 31238862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
    Isakova AA; Artykov AA; Plotnikova EA; Trunova GV; Khokhlova VА; Pankratov AA; Shuvalova ML; Mazur DV; Antipova NV; Shakhparonov MI; Dolgikh DA; Kirpichnikov MP; Gasparian ME; Yagolovich AV
    Int J Biol Macromol; 2024 Jan; 255():128096. PubMed ID: 37972835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
    Reis CR; van der Sloot AM; Natoni A; Szegezdi E; Setroikromo R; Meijer M; Sjollema K; Stricher F; Cool RH; Samali A; Serrano L; Quax WJ
    Cell Death Dis; 2010 Oct; 1(10):e83. PubMed ID: 21368856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
    Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
    Guillaume YC; Lethier L; André C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directed Change in TNFα Specificity to Create DR5 Antagonists.
    Ukrainskaya VM; Bobik TV; Argentova-Stevens A; Slutskaya EA; Kalinin RS; Gabibov AG; Stepanov AV
    Bull Exp Biol Med; 2018 Jul; 165(3):386-389. PubMed ID: 30003423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B
    Gasparian ME; Bychkov ML; Yagolovich AV; Kirpichnikov MP; Dolgikh DA
    Dokl Biochem Biophys; 2017 Nov; 477(1):385-388. PubMed ID: 29297126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
    Kojima Y; Nakayama M; Nishina T; Nakano H; Koyanagi M; Takeda K; Okumura K; Yagita H
    J Biol Chem; 2011 Dec; 286(50):43383-93. PubMed ID: 22020938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
    Kim SL; Min IS; Park YR; Lee ST; Kim SW
    Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
    Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
    Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.